

COVER SHEET

1	4	8	0	2	2				
---	---	---	---	---	---	--	--	--	--

S.E.C. Registration Number

E	U	R	O	-	M	E	D		L	A	B	O	R	A	T	O	R	I	E	S		P	H	I	L	.		
I	N	C	.																									

(Company's Full Name)

1	0	0	0		U	N	I	T	E	D		N	A	T	I	O	N		A	V	E	.		C	O	R	P	.
S	A	N		M	A	R	C	E	L	I	N	O		S	T	.		M	A	N	I	L	A					

(Business Address: No. Street City/Town/Province)

S	a	n	d	r	a		P	i	n	e	d	a
---	---	---	---	---	---	--	---	---	---	---	---	---

Contact Person

5	2	4	0	0	9	1	-	9	8
---	---	---	---	---	---	---	---	---	---

Company Telephone Number

0	8		
---	---	--	--

Month
Fiscal Year

1	4		
---	---	--	--

Day

2 0 0 8

1	7	-	Q		
---	---	---	---	--	--

FORM TYPE

--	--

Month

--	--

Day

Annual Meeting

--	--	--	--	--	--

Secondary License Type, if Applicable

--	--	--

Dept. Requiring this Doc.

--	--	--	--	--	--	--	--	--	--

Amended Articles Number/Section

--	--	--	--	--	--

Total No. of Stockholders

Total Amount of Borrowings

--	--	--	--	--	--

Domestic

--	--	--	--	--	--

Foreign

To be accomplished by SEC Personnel concerned

--	--	--	--	--	--	--	--	--	--

File Number

LCU

--	--	--	--	--	--	--	--	--	--

Document I.D.

Cashier

STAMPS

Remarks - pls. use black ink for scanning purposes

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-Q

ANNUAL REPORT PURSUANT TO SECTION 17
OF THE SECURITIES REGULATION CODE AND SECTION 141
OF THE CORPORATION CODE OF THE PHILIPPINES

1. For the quarterly period ended June 30, 2008
2. SEC Identification Number 148022 3. BIR Tax Identification No. 000-288-655V
4. Exact name of registrant as specified in its charter **EURO-MED LABORATORIES PHIL., INC.**
5. Philippines
(Province, country or other jurisdiction of
incorporation or organization)
6. (SEC Use Only)
Industry Classification Code:
7. 1000 United Nations Avenue cor. San Marcelino St., Manila
Address of principal office 1000
postal code
8. (632) 524-0091 to 98
Issuer's telephone number, including area code
9. Not Applicable
Former name, former address and former fiscal year, if changed since last report

10. Securities registered pursuant to Sections 8 and 12 of the SRC, or Sections 4 and 8 of the RSA

<u>Title of Each Class</u>	<u>Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding</u>
Common Stock	3,221,020,000 shares

11. Are any or all of these securities listed on a Stock Exchange?

Yes [x] No []

If yes, state the name of such stock exchange and the classes of securities listed therein:

Philippine Stock Exchange

Common Stock

12. Check whether the issuer:

(a) has filed all reports required to be filed by Section 17 of the SRC and SRC Rule 17 thereunder, or Section 11 of the RSA and RSA Rule 11(a) -1 thereunder, and Sections 26 and 141 of The Corporation Code of the Philippines during the preceding twelve (12) months (or for such shorter period that the registrant was required to file such reports);

Yes [x] No []

(b) has been subject to such filing requirements for the past ninety (90) days.

Yes [x] No []

EURO-MED LABORATORIES PHIL., INC.
TABLE OF CONTENTS
SEC FORM 17-Q

	<u>Page</u>
Part I FINANCIAL INFORMATION	
Item 1. Financial Statements	4-36
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	1-3
SIGNATURES	3

Part I – Financial Information

Item 1. Financial Statements

See accompanying Interim Financial Statements.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The Company's operations have no seasonal aspects that had a material effect on the financial condition or results of operations. The Company operates regularly for twelve (12) months during the year and does its maintenance jobs during Sundays and holiday breaks. There are no known trends, demands, material commitments for capital expenditures, events, or uncertainties that will have a material impact on the Company's liquidity or have a material favorable or unfavorable impact on net sales/revenue/income from continuing operations. There are no known events that will trigger direct or contingent financial obligation that is material to the Company, including any default or acceleration of an obligation. There are no off-balance sheet transactions, arrangements, obligations and other relationships of the Company with unconsolidated entities or other persons created during the reporting period.

The Company's top five (5) key performance indicators are:

1.) The Company's net sales increased by 5.5% from P1033.8 million for the first half of 2007 to P1,090.8 million for the first half of 2008. The increase in sales was attributed to the increase in local sales. Domestic sales increased by 8.5% from P841.1 million for the first half of 2007 to P912.4 million in first half of 2008. The increase in sales indicator was chosen by management as it discloses the level of performance the Company has attained against the targeted growth. The percentage change is computed by dividing the peso increase in sales by the peso sales during the comparable period of previous year.

2.) Gross profit from sales decreased by 3.4% from P496.1 million for the first half of 2007 to P479.2 million for the first half of 2008. Cost of goods manufactured and sold increased by 13.7% from P537.8 million for the first half of 2007 to P611.6 million for the first half of 2008. As a percentage of net sales, cost of goods manufactured and sold increased from 52% for the first half of 2007 to 56% for the first half of 2008. The gross profit indicator provides information about product selling prices relative to production costs. The percentage change in gross profit is computed by dividing the peso increase(decrease) in gross profit by the peso gross profit during the comparable period of previous year.

3.) Income from operations (income before finance income/cost and miscellaneous income) decreased by 18.6% from P282.1 million for the first half of 2007 to P229.7 million for the first half of 2008. Operating expenses (administration, selling and distribution) increased by 16.6% from P213.9 million for the first half of 2007 to

